GlassScriptPhysician profile
Sujit R Varma
NPI 1013018258
$580,985.31
in general payments reported to CMS, 2019-2025
36 companies · $155K in 2025
The $155K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,421 · 2020: $16K · 2021: $11K · 2022: $118K · 2023: $145K · 2024: $132K · 2025: $155K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $314K · Consulting Fee: $49K · Travel and Lodging: $46K · Honoraria: $14K · Food and Beverage: $8,611 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,000 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $314,394.75 |
| Consulting Fee | $48,509.00 |
| Travel and Lodging | $45,633.04 |
| Honoraria | $13,750.00 |
| Food and Beverage | $8,611.49 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,000.00 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $133,250.01 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $102,108.33 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $77,225.62 | 2020-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Harmony Biosciences LLC | $69,555.20 | 2021-2025 | Wakix |
| Abbvie INC. | $43,715.32 | 2022-2024 | Vraylar |
| E.R. Squibb & Sons, L.L.C. | $38,144.45 | 2024-2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $34,348.65 | 2022-2025 | Quviviq, Quviviq |
| Alkermes, INC. | $32,907.67 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Axsome Therapeutics, INC. | $32,706.49 | 2023-2025 | Sunosi, Auvelity |
| Jazz Pharmaceuticals INC. | $14,395.84 | 2020-2025 | |
| Alvogen INC | $700.00 | 2022 | |
| Livanova USA, INC. | $410.22 | 2021-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Supernus Pharmaceuticals, INC. | $298.74 | 2022-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $214.99 | 2024-2025 | Fanapt |
| Tempus Ai, INC | $155.72 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $106.11 | 2022-2024 | Jornay Pm |
| Uswm, LLC | $103.63 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $101.19 | 2019-2024 | Spravato |
| Corium, LLC | $98.01 | 2021-2024 | Azstarys, Azstarys |
| Eisai INC. | $55.56 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $55.10 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $44.11 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $40.37 | 2024 | Lumryz |
| Allergan, INC. | $33.45 | 2020-2021 | |
| Lundbeck LLC | $27.06 | 2020-2024 | Rexulti |
| Neurocrine Biosciences, INC. | $23.01 | 2019 | |
| Itamar Medical INC | $21.00 | 2023 | Watchpatone |
| Takeda Pharmaceuticals U.S.A., INC. | $17.04 | 2025 | Trintellix |
| Collegium Pharmaceutical, INC. | $16.71 | 2025 | Belbuca |
| Bioxcel Therapeutics, INC. | $16.41 | 2023 | Igalmi |
| Almatica Pharma LLC | $16.13 | 2025 | Loreev Xr |
| Acadia Pharmaceuticals INC | $15.85 | 2021 | |
| Tris Pharma INC | $15.77 | 2025 | Onyda Xr |
| Vertical Pharmaceuticals, LLC | $14.43 | 2019 | |
| Novo Nordisk INC | $13.63 | 2024 | Wegovy |
| Braeburn INC. | $13.49 | 2023 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujit Varma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.